



A service of the National Library of Medicine
and the National Institutes of Health

[My NCBI](#)[\[Sign In\]](#) [\[Register\]](#)[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[Books](#)

Search

PubMed

for "ribonuclease k6"[Substance Name]

[Preview](#)[Go](#)[Clear](#)[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorials](#)[New/Noteworthy](#) [E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

Search

Most Recent Queries

Time Result

[#9](#) Search "ribonuclease k6"[Substance Name]

16:09:10

[4](#)[#4](#) Search Rosenberg Dyer ribonuclease

13:43:26

[30](#)[#3](#) Search Rosenberg Dyer

13:43:13

[43](#)[Clear History](#)[Write to the Help Desk](#)[NCBI](#) | [NLM](#) | [NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 6 2006 15:24:20

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	4	"2003072761".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 13:29
S2	2	"2005214786".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 13:30
S3	2	"20050214786".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 14:39
S4	2	"5866119".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 14:39
S5	1	S4 and glycosyl\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 16:08
S6	14	ribonuclease adj k6!	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 16:09
S7	2	(rosen.in. or baker.in. or birse.in. or choi.in. or fiscella.in. or komatsoulis.in. or moore.in. or ni.in. or olsen.in. or ruben.in. or wei.in. or duan.in. or shi. in.) and S6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/11/15 16:11

Search Report for WO 2003/072761

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04819

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 1/00, 5/10, 15/11, 15/12, 15/63, 15/70, 15/82, 15/85; C12Q 1/68

US CL : 435/6, 243, 320.1, 325, 410, 455, 468, 471; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 243, 320.1, 325, 410, 455, 468, 471; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/091625 A2 (RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY) 06 December 2001 (06.12.2001), pages 4-6, 22-27, 68-69, and 71-74.	1-10, 14, 18, 21
X	KUSTER et al. Characterization and Expression of the Gene for the Human Fc Receptor Gamma Subunit. The Journal of Biological Chemistry. 15 April 1990, Vol. 265, No. 11, pages 6448-6452, see entire document, especially page 6449, column 1 - page 6451, column 2.	1-10, 14, 21

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

30 May 2003 (30.05.2003)

Date of mailing of the international search report

28 JUL 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No.

Authorized officer

Terry A. McKelvey

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04819

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 23
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Please See Continuation Sheet
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-10, 14, 18, and 21 (only as directed to gene 1)

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US03/04819

Continuation of Box I Reason 2:

the claim is drawn to product identified as a binding partner which affects the activity of a polypeptide. The chemical structures of what would constitute binding molecules of a particular polypeptide that affect the activity of the polypeptide are not described in such a way as to be searchable because searches for compounds require a search of structures.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Groups 1-20, claims 1-10, 14, 18, and 21, drawn to nucleic acid, vector, host cell, method of making host cell, method of diagnosing a condition, and gene, only as directed to genes 1-20 of Table 1A, respectively.

Groups 21-40, claims 11-12 and 15-16, drawn to polypeptide and method of making polypeptide, only as directed to genes 1-20 of Table 1A, respectively.

Groups 41-60, claim 13, drawn to antibody, only as directed to genes 1-20 of Table 1A, respectively.

Groups 61-80, claim 17, drawn to method of treating condition, only as directed to genes 1-20 of Table 1A, respectively.

Groups 81-100, claim 19, drawn to method of diagnosing a condition, only as directed to genes 1-20 of Table 1A, respectively.

Groups 101-120, claim 20, drawn to method for diagnosing a binding partner, only as directed to genes 1-20 of Table 1A, respectively.

Groups 121-140, claim 22, drawn to method of identifying an activity, only as directed to genes 1-20 of Table 1A, respectively.

The inventions listed as Groups 1-140 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

PCT Rule 13.2 requires that unity of invention exists only when there is a shared same or corresponding technical feature among the claimed inventions. Each member within each set of groups of inventions is drawn to a polynucleotide or polypeptide of a sequence unrelated to the other members and thus does not share a same or corresponding technical feature with the other members. Each set of groups of inventions has a different technical feature not shared by the other groups: Groups 1-20, 21-40, and 41-60 are directed to nucleic acid, etc, polypeptide, and antibody which are different from each other structurally and functionally and thus do not share a technical feature. Groups 1-20 also contain the first method of use and first method of making corresponding to each group. Groups 61-80 are drawn to a method which has the technical feature of administering a polypeptide to treat a condition, which is not shared by the other groups. Groups 81-100 are drawn to a method which has the technical feature of determining the amount of a polypeptide in a sample, which is not shared by the other groups. Groups 101-120 are drawn to a method which has the technical feature of determining whether a binding partner affects an activity of a polypeptide, which is not shared by the other groups. Groups 121-140 are drawn to a method which has the technical feature of detecting an activity in an assay, which is not shared by the other groups.

INTERNATIONAL SEARCH REPORT

PCT/US03/04819

Continuation of B. FIELDS SEARCHED Item 3:

EAST (USPAT, US PG-PUB, EPO, JPO, Derwent), Dialog OneSearch (biotech databases)

search terms: secret?, human, diagnos?, treat?